COMPANY

Cancer Targeted Technology LLC

HQ: Woodinville, WA source · cancertargetedtechnology.com ↗ · West Coast

Clinical Phase 1

Location: Woodinville, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Prostate Cancer Renal Cell Carcinoma CTT1057 CTT1403

3Trials (company is sponsor)13NIH grants

Timeline

Jul 25, 2025 Grant Government grant — SBIR: $2M (annual award, as published), announced Jul 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Apr 1, 2019 Trial start Phase 1: A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer source ↗
Jan 1, 2018 Trial start Phase 1: CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma source ↗
2016-09 Trial start 1: A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 source ↗

Funding

Last 2 years.

Jul 25, 2025 Government grant — SBIR: $2M (annual award, as published), announced Jul 25, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT03822871	A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer	Phase 1	Completed	Apr 1, 2019	Oct 28, 2022 (actual)
NCT03427476	CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma	Phase 1	Completed	Jan 1, 2018	Aug 31, 2018 (actual)
NCT02916537	A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057	1	Completed	2016-09	Aug 28, 2017 (actual)

NIH awards 13

Annual award amounts. Total $11.6M.

Sep 2, 2024 NIH award 1R44CA290973-01 FY2024: $400,000 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of an In source ↗
Aug 12, 2022 NIH award 5R44CA257799-02 FY2022: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI BOMBA, HUNTER NICOLE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of a Commerci source ↗
Sep 20, 2021 NIH award 1R44CA257799-01A1 FY2021: $1,000,002 awarded for that fiscal year; activity R44 (SBIR); PI BOMBA, HUNTER NICOLE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of a Comm source ↗
Aug 23, 2021 NIH award 5R44CA239461-06 FY2021: $365,867 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Clinical Evaluation source ↗
Jun 9, 2020 NIH award 5R44CA239461-05 FY2020: $1,441,580 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Clinical Evaluatio source ↗
Jul 5, 2019 NIH award 2R44CA239461-04 FY2019: $1,375,908 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Clinical Evaluatio source ↗
Sep 19, 2018 NIH award 1R43CA221511-01A1 FY2018: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of a P source ↗
Feb 19, 2016 NIH award 5R44CA192451-02 FY2016: $923,913 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Clinical Evaluation source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 261201500074C-4-0-2 FY2016: $2,000,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOOD source ↗
Mar 3, 2015 NIH award 1R44CA192451-01 FY2015: $1,076,087 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Clinical Evaluatio source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 261201500074C-0-0-1 FY2015: $300,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODIN source ↗
Sep 23, 2011 NIH award 4R44CA153481-02 FY2011: $1,145,108 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of a n source ↗
Sep 28, 2010 NIH award 1R44CA153481-01A1 FY2010: $307,641 awarded for that fiscal year; activity R44 (SBIR); PI LANGTON-WEBSTER, BEATRICE; recipient as written: CANCER TARGETED TECHNOLOGY, LLC, WOODINVILLE, WA. Development of a n source ↗